-
Comprehensive tumor profiling promises new therapeutic options for patients with advanced cancer
worldpharmanews
May 05, 2019
Comprehensive tumor profiling promises new therapeutic options for patients with advanced cancer.
-
Cabozantinib shows promise as first line treatment for differentiated thyroid cancer
europeanpharmaceuticalreview
May 05, 2019
A kinase inhibitor called cabozantinib could be a viable therapy option for patients with metastatic, radioactive iodine-resistant thyroid cancer…
-
Novel colorectal cancer vaccine shows positive phase I results
europeanpharmaceuticalreview
May 05, 2019
A new vaccine for colorectal cancer has proven to be safe in a small sample of human subjects, opening the way for the next phase of testing.
-
Amgen ignites a social fitness movement to support the fight against heart disease and cancer
worldpharmanews
May 05, 2019
Amgen ignites a social fitness movement to support the fight against heart disease and cancer.
-
Kisqali receives breakthrough therapy designation for advanced breast cancer
europeanpharmaceuticalreview
April 30, 2019
Kisqali receives breakthrough therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with HR+/HER2- advanced or metastatic breast cancer…
-
Cardiff Met develops new cancer treatment
europeanpharmaceuticalreview
April 30, 2019
Cardiff Metropolitan University has been instrumental in the development of a new anti-cancer agent that has the potential to offer a valuable treatment option for cancer…
-
Cancer-fighting nano-robots programmed to seek and destroy tumours
europeanpharmaceuticalreview
April 30, 2019
Study shows first applications of DNA origami for nanomedicine…
-
Microbubbles make breast cancer more susceptible to radiation therapy
europeanpharmaceuticalreview
April 29, 2019
Bursting oxygen-filled microbubbles in breast cancer makes tumours three times more sensitive to radiation therapy in preliminary tests with animal models of the disease…
-
NIR identifies breast cancer patients who will benefit from chemotherapy
europeanpharmaceuticalreview
April 29, 2019
Scientists have developed a new optical imaging system that uses red and near-infrared light to identify breast cancer patients who will respond to chemotherapy…
-
Lilly to withdraw cancer drug Lartruvo from global market
pharmaceutical-technology
April 28, 2019
Eli Lilly has announced an access programme for patients that wish to continue using its cancer drug Lartruvo (olaratumab) as the company prepares to withdraw the medication from markets worldwide.
ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
